Latest Period
Q4 2025
Security Snapshot
PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) Institutional Ownership
CUSIP: 697947109
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
141
Shares (Excl. Options)
9,759,838
Price
$104.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.01 par value
- Symbol
- PVLA on Nasdaq
- Shares outstanding
- 11,842,870
- Price per share
- $130.20
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 9,759,838
- Total reported value
- $1,021,544,191
- % of total 13F portfolios
- 0%
- Share change
- +1,147,526
- Value change
- +$142,062,451
- Number of holders
- 141
- Price from insider filings
- $130.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value is tracked under CUSIP 697947109.
- 141 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 141 to 24 between Q4 2025 and Q1 2026.
- Reported value moved from $1,021,544,191 to $26,747,628.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 141 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 697947109?
CUSIP 697947109 identifies PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 697947109:
Significant Owners of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kaupinen Wes | 15% | $38,555,729 | 1,644,869 | Kaupinen Wes | 13 Dec 2024 | |||
| First Light Asset Management, LLC | 7.5% | $89,137,745 | 887,031 | First Light Asset Management, LLC | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 7.1% | -29% | $88,331,614 | -$30,366,571 | 879,009 | -26% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | -13% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 6% | +22% | $70,982,116 | +$16,164,419 | 706,360 | +29% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Samsara BioCapital, L.P. | 3.1% | -50% | $8,989,600 | -$8,989,600 | 339,743 | -50% | Samsara BioCapital, L.P. | 30 Jun 2025 |
| Dellora Investments LP | 1.3% | $3,306,892 | 141,079 | Dellora Investments LP | 13 Dec 2024 |
As of 31 Dec 2025, 141 institutional investors reported holding 9,759,838 shares of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA). This represents 82% of the company’s total 11,842,870 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.5% | 892,400 | +8.5% | 2.3% | $93,407,508 |
| BVF INC/IL | 7.4% | 879,009 | -24% | 3.1% | $92,005,872 |
| Frazier Life Sciences Management, L.P. | 6.1% | 722,400 | 0% | 2% | $75,613,608 |
| First Light Asset Management, LLC | 6% | 709,141 | +31% | 5.7% | $74,225,788 |
| VANGUARD GROUP INC | 4.7% | 560,616 | +13% | 0% | $58,679,676 |
| BlackRock, Inc. | 4.7% | 559,065 | +15% | 0% | $58,517,334 |
| STATE STREET CORP | 3.6% | 420,462 | +206% | 0% | $44,009,758 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 3.3% | 389,420 | +1016% | 1.1% | $40,760,591 |
| JENNISON ASSOCIATES LLC | 3.3% | 387,483 | +262% | 0.02% | $40,557,846 |
| FEDERATED HERMES, INC. | 3.1% | 368,038 | +8.6% | 0.06% | $38,522,537 |
| Woodline Partners LP | 2.5% | 300,536 | -13% | 0.12% | $31,457,103 |
| ALLIANCEBERNSTEIN L.P. | 2.3% | 269,027 | 0.01% | $28,159,056 | |
| PERCEPTIVE ADVISORS LLC | 2.2% | 266,287 | -33% | 0.51% | $27,872,260 |
| FMR LLC | 2% | 231,760 | +110% | 0% | $24,258,346 |
| MORGAN STANLEY | 1.9% | 220,662 | +59% | 0% | $23,096,692 |
| Artisan Partners Limited Partnership | 1.8% | 211,553 | 0.03% | $22,143,253 | |
| MPM BIOIMPACT LLC | 1.7% | 205,745 | +205% | 2.5% | $21,535,329 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 178,992 | +6.5% | 0% | $18,739,109 |
| FRED ALGER MANAGEMENT, LLC | 1.3% | 150,026 | -20% | 0.06% | $15,703,221 |
| Balyasny Asset Management L.P. | 0.92% | 108,880 | -35% | 0.02% | $11,396,470 |
| SAMSARA BIOCAPITAL, LLC | 0.89% | 104,817 | -50% | 1.1% | $10,971,195 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.86% | 101,748 | 0.17% | $10,649,963 | |
| GOLDMAN SACHS GROUP INC | 0.84% | 98,935 | -58% | 0% | $10,355,526 |
| Clio Asset Management LLC | 0.77% | 91,642 | +0% | 7.4% | $9,592,168 |
| NEXTBio Capital Management LP | 0.7% | 82,686 | 0% | 5.1% | $8,654,744 |
Institutional Holders of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 214,583 | $26,747,628 | +$9,681,726 | $124.65 | 24 |
| 2025 Q4 | 9,759,838 | $1,021,544,191 | +$142,062,451 | $104.67 | 141 |
| 2025 Q3 | 8,525,488 | $534,466,075 | +$183,107,977 | $62.69 | 100 |
| 2025 Q2 | 5,909,706 | $133,205,244 | +$16,635,084 | $22.54 | 64 |
| 2025 Q1 | 5,123,397 | $143,404,590 | +$33,701,617 | $27.99 | 40 |
| 2024 Q4 | 4,033,052 | $48,417,227 | +$48,417,227 | $12.00 | 32 |